» Articles » PMID: 3523247

Natural Course of Insulin Resistance in Type I Diabetes

Overview
Journal N Engl J Med
Specialty General Medicine
Date 1986 Jul 24
PMID 3523247
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

To examine the natural course of insulin action in Type I diabetes, we followed 15 patients prospectively for one year after the diagnosis of diabetes and also performed a cross-sectional study of 53 additional patients who had had diabetes for 2 to 32 years. Two weeks after diagnosis, the rate of glucose uptake during hyperinsulinemia, a measure of insulin action, was 32 percent lower in the patients with diabetes than in 30 matched normal subjects (P less than 0.01), but it rose to normal during the subsequent three months. At three months after diagnosis, 9 of 21 patients (43 percent) were in clinical remission and did not require insulin therapy. In these patients, insulin action was 40 percent greater (P less than 0.002) than in the patients who continued to need insulin treatment. Fasting plasma C-peptide levels were slightly but not significantly higher in the patients who had a remission than in the other patients. In patients who had had diabetes for one year or more, insulin action was also reduced by an average of 40 percent (although there was considerable variation between patients), and it was inversely related to glycemic control and relative body weight. Thus, in patients with newly diagnosed Type I diabetes, a transient normalization of insulin action may occur after an initial reduction, along with a partial recovery of endogenous insulin secretion, and these events may contribute to the development of a clinical remission ("honeymoon" period). A majority of patients with diabetes of long duration are characterized by varying degrees of insulin resistance.

Citing Articles

Lessons learned from the FinnDiane Study: Epidemiology and metabolic risk factors for diabetic kidney disease in type 1 diabetes.

Jansson Sigfrids F, Lithovius R, Groop P, Thorn L Diabet Med. 2024; 42(2):e15431.

PMID: 39235140 PMC: 11733665. DOI: 10.1111/dme.15431.


Clinical and molecular insights into cardiovascular disease in psoriatic patients and the potential protective role of apremilast.

Barbarroja N, Lopez-Medina C, Escudero-Contreras A, Arias-de la Rosa I Front Immunol. 2024; 15:1459185.

PMID: 39170613 PMC: 11335487. DOI: 10.3389/fimmu.2024.1459185.


Alternative therapeutic strategies in diabetes management.

Annicchiarico A, Barile B, Buccoliero C, Nicchia G, Brunetti G World J Diabetes. 2024; 15(6):1142-1161.

PMID: 38983831 PMC: 11229975. DOI: 10.4239/wjd.v15.i6.1142.


Role of Dietary Macronutrient Composition and Fibre Intake in Development of Double Diabetes in Indian Youth.

Oza C, Mandlik R, Khadilkar A, Gondhalekar K, Khadilkar V Indian J Endocrinol Metab. 2024; 28(2):213-219.

PMID: 38911111 PMC: 11189281. DOI: 10.4103/ijem.ijem_90_23.


Double diabetes-when type 1 diabetes meets type 2 diabetes: definition, pathogenesis and recognition.

Bielka W, Przezak A, Moleda P, Pius-Sadowska E, Machalinski B Cardiovasc Diabetol. 2024; 23(1):62.

PMID: 38341550 PMC: 10859035. DOI: 10.1186/s12933-024-02145-x.